Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Technetium (99mTc) medronic acid Technetium (99mTc) medronic acid Technetium (Tc) medronic acid (MDP) is a pharmaceutical product used in nuclear medicine to localize bone metastases as well as other diseases that can alter the natural turn-over in the bone by bone scintigraphy. The drug is a complex of medronic acid, the simplest bisphosphonate, with technetium-99m (Tc), a radionuclide that emits gamma rays. The exact structure of the complex is not known. Tc-MDP must be prepared in a radiopharmacy. It is usually supplied as a "cold kit" to which radioactive Tc from a generator is added. Kit composition may vary between suppliers, but contents typically